Answers are grounded in this paper and cite their sources.
Explores curcumin analogues' effects on cell death in endometrial cancer, suggesting new treatments.
215 Background: Advanced endometrial cancer remains challenging to treat due to limited therapeutic options and drug resistance. Ferroptosis, an iron-dependent form of regulated cell death, offers a potential strategy to overcome resistance. Methods: Human endometrial cancer cell lines (KLE, Hec50co, Ishikawa) were treated with bioavailable curcumin analogues HO-3867 or AKT-100. Ferroptosis-related gene expression was assessed by RNA sequencing, qPCR, and immunoblotting, focusing on heme oxygenase-1 (HMOX1). Intracellular iron and reactive oxygen species (ROS) were quantified using FerroOrange and DCFH-DA staining. Cell viability and clonogenic survival were evaluated via CyQUANT and colony-formation assays. Pharmacological inhibitors (ZnPP, Liproxstatin-1, Z-VAD-FMK) and HMOX1 siRNA were used to dissect ferroptosis and apoptosis contributions. Statistical analyses included one-way ANOVA with Tukey’s post hoc test for multiple comparisons; significance was set at p < 0.05. Results: Both analogues upregulated ferroptosis-associated genes, most prominently HMOX1. AKT-100 markedly increased intracellular iron and ROS. Inhibition of HMOX1, ferroptosis, or apoptosis partially rescued viability, while HMOX1 knockdown enhanced clonogenic survival, confirming its central role in AKT-100–mediated cytotoxicity. Conclusions: HO-3867 and AKT-100 activate HMOX1-driven ferroptosis and apoptosis to suppress endometrial cancer cell growth. These findings support further in vivo evaluation of HMOX1-targeted strategies as a therapeutic approach for advanced endometrial cancer.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: